Dr. Peter van Roessel, MD PhD, completed his MD at Stanford University and his residency training in psychiatry at Columbia University and the New York-Presbyterian Hospital in New York City. He has pursued additional training in psychodynamic psychotherapy (TFP) via the Columbia University Center for Psychoanalytic Training and Research. Prior to joining the clinical faculty at Stanford, he worked for several years as Associate Director of the general research unit of the New York State Psychiatric Institute, a premier state-funded research hospital affiliated with Columbia University, where he provided clinical care for individuals participating in research studies across a spectrum of psychiatric illness, including treatment resistant mood disorders, anxiety disorders, psychosis and substance use disorders.
At Stanford, he sees adult mood and anxiety disorders outpatients through the Assessment Clinics and participates in resident training and patient care as a supervisor in psychodynamic psychotherapy and psychopharmacology. He additionally directs the third-year resident curriculum in psychopathology and psychopharmacology. As a member of the department's Rodriguez Translational Therapeutics Lab, he sees individuals with obsessive-compulsive spectrum disorders for evaluations and research-protocol driven clinical treatment and contributes to and directs clinical neuroscience studies pioneering rapid-acting interventions in OCD.
Dr. van Roessel pursued research training basic neuroscience prior to his clinical training, completing an MPhil in Biology via the Open University, UK, for research performed at the Max Planck Institute for Developmental Biology in Tübingen Germany, and a PhD in molecular and developmental neurobiology at the University of Cambridge, UK. More recently, he has contributed to work in the lab of Dr Julia Kaltschmidt (Stanford) on studies of GABAergic/Glutamatergic interneuronal circuity in mouse. In the Rodriguez Lab, he is pursuing clinically-motivated research interests related to the nature and neural correlates of insight in obsessive-compulsive and related disorders. He received a 2018 NARSAD Young Investigator Award to pursue study of nitrous oxide as a rapid-acting treatment for OCD, he is a 2020-2021 Miller Foundation Fellow, and is a Advanced Fellow in Mental Illness Treatment and Research via the Sierra Pacific Mental Illness Research, Education, and Clinical Center of the Palo Alto VA.
Clinical Associate Professor, Psychiatry and Behavioral Sciences
PhD Training: University of Cambridge (2003) United Kingdom
Board Certification: American Board of Psychiatry and Neurology, Psychiatry (2011)
Residency: New York Presbyterian Hospital - Columbia University (2011) NY
Medical Education: Stanford University School of Medicine (2007) CA